Switch theme
Sign up to access all valuation multiples
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
2015
19
Last FY Revenue $0.5M
Last FY EBITDA -$4.3M
$57.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, ABVC BioPharma achieved revenue of $0.5M and an EBITDA of -$4.3M.
ABVC BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ABVC BioPharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$4.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -852% | XXX | XXX | XXX |
| EBIT | XXX | -$4.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -923% | XXX | XXX | XXX |
| Net Profit | XXX | -$4.9M | XXX | XXX | XXX |
| Net Margin | XXX | -962% | XXX | XXX | XXX |
| Net Debt | XXX | $1.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, ABVC BioPharma's stock price is $3.
ABVC BioPharma has current market cap of $56.0M, and EV of $57.2M.
See ABVC BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $57.2M | $56.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, ABVC BioPharma has market cap of $56.0M and EV of $57.2M.
ABVC BioPharma's trades at 112.2x EV/Revenue multiple, and -13.2x EV/EBITDA.
Equity research analysts estimate ABVC BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ABVC BioPharma's P/E ratio is not available.
See valuation multiples for ABVC BioPharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $56.0M | XXX | $56.0M | XXX | XXX | XXX |
| EV (current) | $57.2M | XXX | $57.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 112.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -13.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -12.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -11.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -31.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialABVC BioPharma's revenue per employee in the last FY averaged $27K, while opex per employee averaged $0.3M for the same period.
ABVC BioPharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ABVC BioPharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ABVC BioPharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -852% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1023% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jyong Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ABVC BioPharma acquired XXX companies to date.
Last acquisition by ABVC BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . ABVC BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was ABVC BioPharma founded? | ABVC BioPharma was founded in 2015. |
| Where is ABVC BioPharma headquartered? | ABVC BioPharma is headquartered in United States of America. |
| How many employees does ABVC BioPharma have? | As of today, ABVC BioPharma has 19 employees. |
| Who is the CEO of ABVC BioPharma? | ABVC BioPharma's CEO is Dr. Uttam Yashwant Patil. |
| Is ABVC BioPharma publicy listed? | Yes, ABVC BioPharma is a public company listed on NAS. |
| What is the stock symbol of ABVC BioPharma? | ABVC BioPharma trades under ABVC ticker. |
| When did ABVC BioPharma go public? | ABVC BioPharma went public in 2004. |
| Who are competitors of ABVC BioPharma? | Similar companies to ABVC BioPharma include e.g. Jyong Biotech, |
| What is the current market cap of ABVC BioPharma? | ABVC BioPharma's current market cap is $56.0M |
| Is ABVC BioPharma profitable? | Yes, ABVC BioPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
